Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis

Giovanni Caocci, Olga Mulas, Mario Annunziata, Luigiana Luciano, Massimiliano Bonifacio, Ester Maria Orlandi, Patrizia Pregno, Sara Galimberti, Antonella Russo Rossi, Elisabetta Abruzzese, Alessandra Iurlo, Bruno Martino, Nicola Sgherza, Gianni Binotto, Fausto Castagnetti, Antonella Gozzini, Claudio Fozza, Monica Bocchia, Anna Sicuranza, Fabio StagnoFabio Efficace, Emilio Usala, Fiorenza De Gregorio, Luigi Scaffidi, Chiara Elena, Francesca Pirillo, Claudia Baratè, Malgorzata Monika Trawinska, Daniele Cattaneo, Claudia Labate, Gabriele Gugliotta, Matteo Molica, Giorgina Specchia, Giorgio La Nasa, Robin Foà, Massimo Breccia

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)E159-E161
JournalAmerican Journal of Hematology
Volume93
Issue number7
DOIs
Publication statusPublished - 2018

ASJC Scopus subject areas

  • Hematology

Cite this

Caocci, G., Mulas, O., Annunziata, M., Luciano, L., Bonifacio, M., Orlandi, E. M., Pregno, P., Galimberti, S., Russo Rossi, A., Abruzzese, E., Iurlo, A., Martino, B., Sgherza, N., Binotto, G., Castagnetti, F., Gozzini, A., Fozza, C., Bocchia, M., Sicuranza, A., ... Breccia, M. (2018). Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. American Journal of Hematology, 93(7), E159-E161. https://doi.org/10.1002/ajh.25102